𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A double-blind, randomized, comparative study of Dysport® vs. Botox® in primary palmar hyperhidrosis

✍ Scribed by M. Simonetta Moreau; C. Cauhepe; J.P. Magues; J.M. Senard

Book ID
108667348
Publisher
John Wiley and Sons
Year
2003
Tongue
English
Weight
183 KB
Volume
149
Category
Article
ISSN
0007-0963

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Respective potencies of Botox® and Dyspo
Respective potencies of Botox® and Dysport® in a human skin model: A randomized, double-blind study
✍ Gottfried Kranz; Dietrich Haubenberger; Bernhard Voller; Martin Posch; Peter Sch 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 203 KB

## Abstract Mouse units used to quantify the activity of botulinum A toxin preparations are not equivalent and issues concerning efficacy and safety remain with regard to their respective potencies and diffusion qualities in human tissue. We compared the effects of Botox® (BOT) and Dysport® (DYS) i

Efficacy and safety of botulinum type A
Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: Results of the first US randomized, double-blind, placebo-controlled study
✍ Daniel Truong; Drake D. Duane; Joseph Jankovic; Carlos Singer; Lauren C. Seeberg 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 89 KB

## Abstract Botulinum toxin type A (Dysport) has been shown in European studies to be a safe and effective treatment for cervical dystonia. This multicenter, double‐blind, randomized, controlled trial assessed the safety and efficacy of Dysport in cervical dystonia patients in the United States. Ei

A randomized controlled double blind stu
A randomized controlled double blind study of zuclopenthixol acetate compared to haloperidol in acute psychosis
✍ S. Brook; M. Berk; S. Selemani; J. Kolloori; I. Nzo 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 88 KB 👁 3 views

This study is a double blind randomized controlled trial comparing zuclopenthixol acetate to haloperidol administered parenterally initially and followed by oral medication for 28 days in the treatment of acute psychosis. The sample included 44 patients with schizophrenia, schizophreniform disorder